ROVI — Laboratorios Farmaceuticos Rovi SA Cashflow Statement
0.000.00%
- €2.62bn
- €2.71bn
- €763.75m
- 94
- 20
- 13
- 33
Annual cashflow statement for Laboratorios Farmaceuticos Rovi SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 72.6 | 183 | 258 | 220 | 178 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 1.77 | -1.6 | 0.137 | 1.96 | 0.926 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -47.1 | -53 | -43.4 | -133 | -68.4 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 46.9 | 149 | 238 | 113 | 138 |
Capital Expenditures | -39.7 | -40.9 | -51.4 | -55.2 | -62.2 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.067 | 0.101 | -5.77 | 3.16 | -18.8 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -39.6 | -40.8 | -57.2 | -52 | -81.1 |
Financing Cash Flow Items | -0.299 | -0.288 | 1.08 | 2.39 | 3.64 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -21.5 | -62.7 | -155 | -161 | -55.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -14.3 | 45.9 | 25.9 | -99.6 | 1.86 |